Anti-Covid drug developed by DRDO

  • The Drugs Controller General of India (DCGI) has approved the emergency use of Drug 2-deoxy-D-glucose (2-DG) as an adjunct therapy in moderate to severe Covid-19 patients. 
DEVELOPMENT
  • The Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of Defence Research and Development Organisation (DRDO), has developed the drug, in collaboration with Dr Reddy’s Laboratories, Hyderabad.
  • In April 2020, during the first wave of the pandemic, INMAS-DRDO scientists conducted had laboratory experiments with the help of Centre for Cellular and Molecular Biology (CCMB), Hyderabad.
  • It found that this molecule works effectively against SARS-CoV-2 virus and inhibits the viral growth. 
WORKING
  • 2-DG, works by preventing the supply of glucose molecules to the cancerous cells, which need glucose for survival. 
  • With the drug stopping the glucose supply, the cells start dying. 
  • The drug comes in powder form in sachet, which is taken orally by dissolving it in water. 
  • It accumulates in the virus infected cells and prevents virus growth by stopping viral synthesis and energy production. 
  • Its selective accumulation in virally infected cells makes this drug unique.

Comments

Popular posts from this blog

Hamas V. PLO

G7 global corporate Tax Deal

The statue of Swami Vivekananda at the JNU campus